Pentosan Polysulfate (Elmiron) Lawsuit in New York

Pentosan polysulfate sodium, sold as Elmiron, is a bladder pain medication linked to a rare form of eye damage called pigmentary maculopathy, which can cause blurred vision, difficulty reading, and even permanent vision loss. Lawsuits allege that manufacturer Janssen Pharmaceuticals knew of this risk but failed to warn patients and doctors for years. The FDA required a label update in 2020 acknowledging the eye damage risk.

Yes. New York residents who took Elmiron and suffered vision problems may be eligible to file a product liability lawsuit. Under CPLR §214, New York’s standard personal injury statute of limitations is three years from the date you discovered—or reasonably should have discovered—the injury. Because macular damage can develop subtly over time, the discovery rule is particularly important; consult a NY attorney promptly to evaluate your specific timeline.

Potential plaintiffs generally include anyone who took pentosan polysulfate sodium (Elmiron) for six months or more and was later diagnosed with pigmentary maculopathy or other unexplained retinal damage. An ophthalmology evaluation documenting the specific pattern of retinal changes associated with Elmiron is key evidence. You do not need to have stopped taking the drug to explore your legal options.

See a retinal specialist or ophthalmologist and ask them to evaluate you specifically for Elmiron-associated maculopathy—get all findings in writing. Gather your prescription history, pharmacy records, and any prior eye exam results. Then contact a NY personal injury attorney experienced in pharmaceutical litigation as soon as possible, because waiting can jeopardize your right to recover under New York’s statute of limitations.